

Loramet

Preparation Date 08-Dec-2006

Revision Date 27-Mar-2007

Revision Number 1

### 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**Product Name** Loramet  
**Common Name** Not available  
**Chemical Name** Not applicable  
**Synonyms** Lormetazepam  
**Product Use** Pharmaceutical product  
**Classification** Anxiolytics, Sedatives, and Hypnotics

**Supplier** Wyeth  
P.O. Box 8299  
Philadelphia, PA 19101 USA.  
Telephone: 1-610-688-4400

**Emergency Telephone Number** Chemtrec USA, Puerto Rico, Canada 1-800-424-9300  
Chemtrec International 1-703-527-3887

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

### 3. HAZARDS IDENTIFICATION

#### Emergency Overview

This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

**Appearance** Pharmaceutical Tablet      **Physical State** Solid      **Odor** Not available

#### Potential Physical Hazards

Powders and solids are presumed to be combustible.

#### Potential Health Effects

**Eyes**

Not available

**Skin**

Not available

**Inhalation**

Not available

**Ingestion**

The most common effects may include drowsiness, mental confusion, lethargy, dizziness, lightheadedness, weakness, unsteadiness, slurred speech, abdominal or stomach cramps or pain, blurred vision, changes in libido, constipation, diarrhea, dryness of mouth or increased thirst, euphoria, headache, increased bronchial secretions or excessive salivation, muscle spasm, nausea, vomiting, problems with urination, tremor, and unusual tiredness or weakness.

May cause harm to the unborn child. May cause harm to breastfed babies.

Please see Patient Package Insert for further information.

**Therapeutic Target Organ(s)**

Central nervous system.

Not listed by OSHA, NTP or IARC.

**Potential Environmental Effects** There is no known ecological information for this product.

#### 4. FIRST AID MEASURES

**Eye Contact** In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.

**Skin Contact** Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

**Inhalation** Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.

**Ingestion** If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

**Aggravated Medical Conditions** Strong sedative effect.

#### 5. FIRE-FIGHTING MEASURES

**Flammable Properties** Not flammable

**Extinguishing Media**

**Suitable Extinguishing Media** Use water spray, foam, dry chemical or carbon dioxide.  
**Unsuitable Extinguishing Media** Do NOT use water jet.

**Fire Fighting** Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.

**Hazardous Combustion Products** Carbon oxides, nitrogen oxides.

**Protective Equipment and Precautions for Firefighters** In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

#### 6. ACCIDENTAL RELEASE MEASURES

**Personal Precautions** Refer to protective measures listed in Sections 7 and 8.

**Environmental Precautions** Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.

**Methods for Containment** Not available

**Methods for Cleaning up** Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.

#### 7. HANDLING AND STORAGE

**Handling** For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.

**Storage** No special safety precautions required. Keep container tightly closed.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Common Name**  
Lormetazepam

**Exposure Guideline**  
0.005 mg/m<sup>3</sup> (Schering OEG)

**Engineering Controls**

Apply technical measures to comply with the occupational exposure guideline. Local exhaust ventilation is needed for limited open handling or where aerosols may be generated.

**Personal Protective Equipment**

**Eye/face Protection**  
**Skin Protection**  
**Respiratory Protection**

Provide eye protection based on risk assessment.  
Wear nitrile or latex gloves. Wear protective garment.  
Base respirator selection on a risk assessment.

**General Hygiene Considerations**

When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands before breaks and at the end of workday.

**Other**

Limit access to only personnel trained in the safe handling of this material Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance

## 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Appearance</b>	Pharmaceutical Tablet	<b>Physical State</b>	Solid
<b>Color</b>	Not available	<b>Odor</b>	Not available
<b>Odor Threshold</b>	Not available		
<b>pH</b>	Not available		
<b>Specific Gravity</b>	Not applicable	<b>Water Solubility</b>	Practically insoluble in water
<b>Solubility</b>	Not applicable	<b>Evaporation Rate</b>	Not applicable
<b>Partition Coefficient (n-octanol/water)</b>	Not available	<b>Vapor Pressure</b>	Not applicable
<b>Boiling Point</b>	Not available	<b>Autoignition Temperature</b>	Not available
<b>Flash Point</b>	Not available	<b>Melting Point</b>	Not available
<b>Flammability Limits in Air</b>	<b>Upper</b> Not applicable	<b>Lower</b> Not applicable	
<b>Explosion Limits</b>	<b>Upper</b> Not applicable	<b>Lower</b> Not applicable	

## 10. STABILITY AND REACTIVITY

<b>Chemical Stability</b>	Stable at room temperature.
<b>Conditions to Avoid</b>	No data available
<b>Materials to Avoid</b>	No materials to be especially mentioned.
<b>Hazardous Decomposition Products</b>	None under normal use.
<b>Possibility of Hazardous Reactions</b>	None under normal use.

## 11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

**Acute Toxicity****Lormetazepam**

<b>LD50 Oral</b>	>5000 mg/kg rats
<b>Acute Dermal Irritation</b>	Not a skin irritant.
<b>Primary Eye Irritation</b>	Mild eye irritation.
<b>Sensitization</b>	Not applicable

**Multiple Dose Toxicity****Lormetazepam**

<b>No Toxicologic Effect Dose/Species/Study Length:</b>	Not applicable
---	----------------

**Maximum Tolerated Dose (MTD), Oral****Lormetazepam**

<b>Carcinogenicity</b>	No studies to assess the carcinogenic potential have been performed.
<b>Genetic Toxicity</b>	No studies to assess the mutagenic potential have been performed.
<b>Reproductive Toxicity</b>	No data available
<b>Developmental Toxicity</b>	Reproduction studies in rats and rabbits revealed no evidence of teratogenic effect after the administration of maternally toxic doses.

**Lormetazepam**

<b>Target Organ(s) of Toxicity</b>	No data available
------------------------------------	-------------------

**12. ECOLOGICAL INFORMATION**

The following effects are based on the Active Pharmaceutical Ingredient.

**Chemical Fate Information** Not available

**Ecotoxicity** Not available

**13. DISPOSAL CONSIDERATIONS**

**Waste Disposal Method** Dispose of in accordance with local and national regulations.

**14. TRANSPORT INFORMATION**

**Transport Information** This material is not classified as hazardous for transport.

**15. REGULATORY INFORMATION**

According to present data no classification and labeling is required according to Directives 67/548/EEC or 1999/45/EC.

**16. OTHER INFORMATION**

---

**16. OTHER INFORMATION**

<b>Prepared By</b>	Wyeth Department of Environment, Health & Safety
<b>Format</b>	This MSDS was prepared in accordance with Directive 2001/58/EC.
<b>List of References</b>	See Patient Package Insert for more information.
<b>Revision Summary</b>	Changes to composition.

## Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

**End of MSDS**